TL;DR: The Centers for Medicare & Medicaid Services modified NCD 258 for transillumination light scanning (diaphanography), effective January 9, 2026. Medicare does not cover this procedure. Here's what billing teams need to know.

This is a non-coverage determination. The CMS diaphanography coverage policy under NCD 258 in the Medicare system is clear: program payment is not made for transillumination light scanning used to detect breast cancer or other breast disease. No specific CPT or HCPCS codes are listed in the policy document itself. If your team is billing for this procedure — or considering it — stop now and read this first.


Quick-Reference Table

Field Detail
Payer CMS (Centers for Medicare & Medicaid Services)
Policy Transillumination Light Scanning or Diaphanography — NCD 258
Policy Code NCD 258
Change Type Modified
Effective Date 2026-01-09
Impact Level Low (non-coverage is unchanged; modification is administrative)
Specialties Affected Radiology, breast imaging, diagnostic testing, oncology
Key Action Do not submit Medicare claims for diaphanography — deny at charge capture, not at claims submission

CMS Transillumination Light Scanning Coverage Criteria and Medical Necessity Requirements 2026

NCD 258 is a National Coverage Determination governing Medicare coverage of transillumination light scanning — also called diaphanography — for breast cancer and breast disease detection. The Centers for Medicare & Medicaid Services maintains that this procedure does not meet medical necessity standards for Medicare reimbursement.

The policy language is direct: the usefulness of transillumination light scanning, compared to existing breast cancer detection methods, has not been clearly established. CMS states that further study is needed before this technology can be assigned a defined role in breast cancer diagnosis. Until that happens, Medicare program payment is not allowed.

This is not a "covered with conditions" situation. There is no clinical scenario, diagnosis code, or documentation pathway that unlocks reimbursement for this procedure under Medicare. No prior authorization process exists — because prior authorization only applies to covered services. Diaphanography is simply non-covered.

The CMS diaphanography coverage policy has not changed in substance. The modification recorded on January 9, 2026 appears administrative. But any update to an NCD is worth reviewing — especially if your practice has recently acquired imaging equipment marketed as transillumination or light-based breast scanning.


CMS Transillumination Light Scanning Exclusions and Non-Covered Indications

The exclusion here is total. CMS does not cover transillumination light scanning or diaphanography for any breast-related indication under Medicare. That includes:

#Excluded Procedure
1Breast cancer screening
2Diagnostic workup for a palpable breast mass
3Follow-up imaging after abnormal mammography
+ 1 more exclusions

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

The policy categorizes this technology as lacking established clinical usefulness — not as unsafe, but as unproven relative to existing methods. Mammography, ultrasound, and MRI have defined roles under Medicare. Diaphanography does not.

This distinction matters for your billing team. "Unproven" is different from "investigational" in some contexts, but under NCD 258, the outcome is the same: no Medicare payment. Don't confuse the policy's acknowledgment that the technology "appears safe" as a pathway to coverage. Safety and medical necessity are separate determinations, and CMS has only affirmed the former.

If a provider on your team believes this technology has evolved and warrants reconsideration, that's a clinical and regulatory conversation — not a billing workaround. Reconsideration requests go through the formal NCD reconsideration process, not through claim submission.


Coverage Indications at a Glance

Indication Status Relevant Codes Notes
Breast cancer detection via transillumination light scanning Not Covered None listed in NCD 258 NCD-level denial; no medical necessity pathway exists
Other breast disease detection via diaphanography Not Covered None listed in NCD 258 Same NCD applies; no coverage for any breast disease indication

This policy is now in effect (since 2026-03-12). Verify your claims match the updated criteria above.

CMS Diaphanography Billing Guidelines and Action Items 2026

The effective date of January 9, 2026 applies to this modified version of NCD 258. Your action items are straightforward, but skipping any one of them creates claim denial exposure.

#Action Item
1

Audit your charge master now. Search for any charge description that references transillumination, diaphanography, or light-based breast scanning. If those charges exist, flag them for removal or suppression from Medicare claims before they generate a submission.

2

Do not submit Medicare claims for this service. This is not a case where you submit and appeal — NCD 258 provides no coverage pathway. Submitting a claim you know is non-covered raises compliance risk beyond simple claim denial.

3

Train your front desk and scheduling teams. If a provider orders this procedure, the non-coverage determination needs to surface before the patient appointment — not after the claim is denied. Use an Advance Beneficiary Notice (ABN) process if you plan to bill the patient directly.

+ 3 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for Transillumination Light Scanning Under NCD 258

Covered CPT Codes

The policy does not list any covered CPT or HCPCS codes. Transillumination light scanning is not covered under NCD 258. There are no codes to bill for this service under Medicare.

Not Covered / Experimental Codes

NCD 258 does not assign specific CPT or HCPCS codes to this procedure. The policy applies to transillumination light scanning and diaphanography as a technology category. If your Medicare Administrative Contractor (MAC) has issued a local coverage determination (LCD) that assigns a specific code to this procedure in your region, that local guidance governs — but the NCD-level non-coverage takes precedence. Check with your MAC for any region-specific coding guidance.

A Note on Coding This Procedure

Because no codes are specified in NCD 258, billing teams sometimes assume a miscellaneous or unlisted code could capture the service. It cannot — at least not for Medicare reimbursement. Miscellaneous codes don't create a pathway around an NCD non-coverage determination. The absence of a listed code is not a gap to exploit. It reflects the fact that CMS has not assigned this procedure a billable code in the Medicare fee schedule because it doesn't intend to pay for it.

If your practice uses a code for this service in your charge master — whatever that code is — it should not be routed to Medicare claims. Period.

Key ICD-10-CM Diagnosis Codes

No ICD-10-CM codes are specified in NCD 258. The non-coverage applies regardless of the diagnosis driving the order.


Get the Full Picture

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee